小胶质细胞
特雷姆2
神经科学
转录组
阿尔茨海默病
淀粉样蛋白(真菌学)
疾病
人脑
趋化因子
神经退行性变
病理
医学
生物
免疫系统
免疫学
炎症
基因
基因表达
遗传学
作者
Renzo Mancuso,Nicola Fattorelli,Anna Martínez‐Muriana,Emma Davis,Leen Wolfs,Johanna Van Den Daele,Ivana Geric,Jessie Premereur,Paula Polanco,Baukje Bijnens,Pranav Preman,Lutgarde Serneels,Suresh Poovathingal,Sriram Balusu,Catherine M. Verfaillie,Mark Fiers,Bart De Strooper
标识
DOI:10.1038/s41593-024-01600-y
摘要
Microglia are central players in Alzheimer's disease pathology but analyzing microglial states in human brain samples is challenging due to genetic diversity, postmortem delay and admixture of pathologies. To circumvent these issues, here we generated 138,577 single-cell expression profiles of human stem cell-derived microglia xenotransplanted in the brain of the AppNL-G-F model of amyloid pathology and wild-type controls. Xenografted human microglia adopt a disease-associated profile similar to that seen in mouse microglia, but display a more pronounced human leukocyte antigen or HLA state, likely related to antigen presentation in response to amyloid plaques. The human microglial response also involves a pro-inflammatory cytokine/chemokine cytokine response microglia or CRM response to oligomeric Aβ oligomers. Genetic deletion of TREM2 or APOE as well as APOE polymorphisms and TREM2R47H expression in the transplanted microglia modulate these responses differentially. The expression of other Alzheimer's disease risk genes is differentially regulated across the distinct cell states elicited in response to amyloid pathology. Thus, we have identified multiple transcriptomic cell states adopted by human microglia in a multipronged response to Alzheimer's disease-related pathology, which should be taken into account in translational studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI